Concentrix [CNXC] vs Accenture plc [ACN] Detailed Stock Comparison
Concentrix
NASDAQ
Loading...
Accenture plc
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Concentrix wins in 10 metrics, Accenture plc wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Concentrix | Accenture plc | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.99 | 20.17 | Concentrix |
| Price-to-Book Ratio | 0.70 | 5.17 | Concentrix |
| Debt-to-Equity Ratio | 135.96 | 25.88 | Accenture plc |
| PEG Ratio | -0.36 | 1.38 | Concentrix |
| EV/EBITDA | 6.03 | 13.46 | Concentrix |
| Profit Margin (TTM) | 2.54% | 11.61% | Accenture plc |
| Operating Margin (TTM) | 6.83% | 16.83% | Accenture plc |
| EBITDA Margin (TTM) | 6.83% | 16.83% | Accenture plc |
| Return on Equity | 5.85% | 26.93% | Accenture plc |
| Return on Assets (TTM) | 3.78% | 11.24% | Accenture plc |
| Free Cash Flow (TTM) | $428.73M | $8.61B | Accenture plc |
| Dividend Yield | 3.07% | 1.87% | Concentrix |
| 1-Year Return | -25.56% | -22.25% | Accenture plc |
| Price-to-Sales Ratio (TTM) | 0.31 | 2.31 | Concentrix |
| Enterprise Value | $8.51B | $158.38B | Accenture plc |
| EV/Revenue Ratio | 0.88 | 2.31 | Concentrix |
| Gross Profit Margin (TTM) | 35.09% | 32.87% | Concentrix |
| Revenue per Share (TTM) | $150 | $109 | Concentrix |
| Earnings per Share (Diluted) | $3.65 | $12.57 | Accenture plc |
| Beta (Stock Volatility) | 0.58 | 1.29 | Concentrix |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Concentrix vs Accenture plc Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Concentrix | 4.90% | 8.05% | -14.47% | -7.35% | 12.90% | 19.59% |
| Accenture plc | 2.06% | 4.94% | -9.67% | -18.09% | -28.77% | -25.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Concentrix | -25.56% | -60.16% | -34.91% | -34.91% | -34.91% | -34.91% |
| Accenture plc | -22.25% | -13.08% | 6.64% | 170.35% | 596.59% | 951.24% |
Performance & Financial Health Analysis: Concentrix vs Accenture plc
| Metric | CNXC | ACN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.99B | $157.95B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 566,426 | 4,126,942 |
| 90 Day Avg. Volume | 639,722 | 4,428,574 |
| Last Close | $52.07 | $259.22 |
| 52 Week Range | $36.28 - $77.00 | $236.67 - $398.35 |
| % from 52W High | -32.38% | -34.93% |
| All-Time High | $208.48 (Feb 07, 2022) | $417.37 (Dec 27, 2021) |
| % from All-Time High | -75.02% | -37.89% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.08% |
| Quarterly Earnings Growth | -0.37% | 0.14% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.12% |
| Operating Margin (TTM) | 0.07% | 0.17% |
| Return on Equity (TTM) | 0.06% | 0.27% |
| Debt to Equity (MRQ) | 135.96 | 25.88 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $67.99 | $49.07 |
| Cash per Share (MRQ) | $5.44 | $15.47 |
| Operating Cash Flow (TTM) | $713.97M | $10.95B |
| Levered Free Cash Flow (TTM) | $689.82M | $9.15B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.07% | 1.87% |
| Last 12-Month Dividend | $1.62 | $5.73 |
Valuation & Enterprise Metrics Analysis: Concentrix vs Accenture plc
| Metric | CNXC | ACN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.99 | 20.17 |
| Forward P/E | 3.85 | 18.02 |
| PEG Ratio | -0.36 | 1.38 |
| Price to Sales (TTM) | 0.31 | 2.31 |
| Price to Book (MRQ) | 0.70 | 5.17 |
| Market Capitalization | ||
| Market Capitalization | $2.99B | $157.95B |
| Enterprise Value | $8.51B | $158.38B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.88 | 2.31 |
| Enterprise to EBITDA | 6.03 | 13.46 |
| Risk & Other Metrics | ||
| Beta | 0.58 | 1.29 |
| Book Value per Share (MRQ) | $67.99 | $49.07 |
Financial Statements Comparison: Concentrix vs Accenture plc
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CNXC | ACN |
|---|---|---|
| Revenue/Sales | $2.37B | $17.73B |
| Cost of Goods Sold | $1.52B | $11.90B |
| Gross Profit | $855.90M | $5.83B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $168.87M | $2.98B |
| EBITDA | $334.50M | $3.31B |
| Pre-Tax Income | $100.79M | $2.95B |
| Income Tax | $30.54M | $707.18M |
| Net Income (Profit) | $70.26M | $2.24B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CNXC | ACN |
|---|---|---|
| Cash & Equivalents | $308.00M | $9.63B |
| Total Current Assets | $2.96B | $27.42B |
| Total Current Liabilities | $1.79B | $18.77B |
| Long-Term Debt | $4.90B | $7.33B |
| Total Shareholders Equity | $4.03B | $31.55B |
| Retained Earnings | $1.24B | $26.45B |
| Property, Plant & Equipment | $0 | $4.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CNXC | ACN |
|---|---|---|
| Operating Cash Flow | $231.10M | $2.96B |
| Capital Expenditures | $-55.79M | $-169.11M |
| Free Cash Flow | $180.74M | $3.52B |
| Debt Repayment | $-1.45B | $0 |
| Common Stock Repurchase | $-46.82M | $-1.80B |
Short Interest & Institutional Ownership Analysis
| Metric | CNXC | ACN |
|---|---|---|
| Shares Short | 7.06M | 12.40M |
| Short Ratio | 10.29 | 3.49 |
| Short % of Float | 0.13% | 0.02% |
| Average Daily Volume (10 Day) | 566,426 | 4,126,942 |
| Average Daily Volume (90 Day) | 639,722 | 4,428,574 |
| Shares Outstanding | 64.24M | 625.28M |
| Float Shares | 35.84M | 621.78M |
| % Held by Insiders | 0.16% | 0.00% |
| % Held by Institutions | 0.97% | 0.82% |
Dividend Analysis & Yield Comparison: Concentrix vs Accenture plc
| Metric | CNXC | ACN |
|---|---|---|
| Last 12-Month Dividend | $1.62 | $5.73 |
| Last 12-Month Dividend Yield | 3.07% | 1.87% |
| 3-Year Avg Annual Dividend | $1.30 | $5.39 |
| 3-Year Avg Dividend Yield | 0.44% | 0.41% |
| 3-Year Total Dividends | $3.89 | $16.17 |
| Ex-Dividend Date | Jul 25, 2025 | Apr 10, 2025 |